Needham analyst Mike Matson reiterated a Hold rating on CONMED (NYSE: CNMD).The analyst commented: 'CNMD's 3Q25 revenue and EPS beat ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE